RILPIVIRINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H18N6.ClH
Molecular Weight	402.879
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2

InChI

InChIKey=KZVVGZKAVZUACK-BJILWQEISA-N

InChI=1S/C22H18N6.ClH/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19;/h3-9,11-13H,1-2H3,(H2,25,26,27,28);1H/b4-3+;

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202022s008lbledt.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/?term=19933797

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is active against wild-type and NNRTI-resistant HIV-1. Rilpivirine is a diarylpyrimidinethat inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Reverse transcriptase/RNaseH (UniProtKB: Q72547) 2 Target ID: Reverse transcriptase/RNaseH (UniProtKB: Q72547) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202022s008lbledt.pdf	Inhibitor 8297		14.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 151 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202022s008lbledt.pdf	Primary		Approved 8429	EDURANT Approved Use In combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy. Launch Date 2011

C_max

Value	Dose	Co-administered	Analyte	Population
0.14 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27187753/	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RILPIVIRINE plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: FED
121 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29335895/	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RILPIVIRINE plasma	Homo sapiens population: PREGNANT age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2.38 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27187753/	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RILPIVIRINE plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: FED
1792 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29335895/	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RILPIVIRINE plasma	Homo sapiens population: PREGNANT age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29335895/	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:		RILPIVIRINE plasma	Homo sapiens population: PREGNANT age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
150 mg 1 times / day multiple, oral Highest studied dose Dose: 150 mg, 1 times / day Route: oral Route: multiple Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19926964 Page: p.62	unhealthy, 21–66 n = 91 Health Status: unhealthy Condition: HIV-1 infection Age Group: 21–66 Sex: M+F Population Size: 91 Sources: https://pubmed.ncbi.nlm.nih.gov/19926964 Page: p.62	Disc. AE: Alanine aminotransferase increase, Aspartate aminotransferase increased... AEs leading to discontinuation/dose reduction: Alanine aminotransferase increase Aspartate aminotransferase increased Sources: https://pubmed.ncbi.nlm.nih.gov/19926964 Page: p.62
25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1	unhealthy n = 686 Health Status: unhealthy Condition: HIV-1 infection Population Size: 686 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1	Disc. AE: Depressive disorders, Suicide attempt... AEs leading to discontinuation/dose reduction: Depressive disorders (severe, 1%) Suicide attempt (0.29%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1
25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.3	unhealthy n = 686 Health Status: unhealthy Condition: HIV-1 infection Population Size: 686 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.3	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (0.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.3
25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1	Disc. AE: Fat redistribution, Immune reconstitution syndrome... AEs leading to discontinuation/dose reduction: Fat redistribution Immune reconstitution syndrome Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Alanine aminotransferase increase	Disc. AE	150 mg 1 times / day multiple, oral Highest studied dose Dose: 150 mg, 1 times / day Route: oral Route: multiple Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19926964 Page: p.62	unhealthy, 21–66 n = 91 Health Status: unhealthy Condition: HIV-1 infection Age Group: 21–66 Sex: M+F Population Size: 91 Sources: https://pubmed.ncbi.nlm.nih.gov/19926964 Page: p.62
Aspartate aminotransferase increased	Disc. AE	150 mg 1 times / day multiple, oral Highest studied dose Dose: 150 mg, 1 times / day Route: oral Route: multiple Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19926964 Page: p.62	unhealthy, 21–66 n = 91 Health Status: unhealthy Condition: HIV-1 infection Age Group: 21–66 Sex: M+F Population Size: 91 Sources: https://pubmed.ncbi.nlm.nih.gov/19926964 Page: p.62
Suicide attempt	0.29% Disc. AE	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1	unhealthy n = 686 Health Status: unhealthy Condition: HIV-1 infection Population Size: 686 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1
Depressive disorders	severe, 1% Disc. AE	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1	unhealthy n = 686 Health Status: unhealthy Condition: HIV-1 infection Population Size: 686 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1
Rash	0.1% Disc. AE	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.3	unhealthy n = 686 Health Status: unhealthy Condition: HIV-1 infection Population Size: 686 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.3
Fat redistribution	Disc. AE	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1
Immune reconstitution syndrome	Disc. AE	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf Page: p.1

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:68606	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:68606
ChemicalBook	CB81454833	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB81454833
MolPort	MolPort-006-170-051	https://www.molport.com/shop/molecule-link/MolPort-006-170-051
ZINC	ZINC000001554274	http://zinc15.docking.org/substances/ZINC000001554274
eMolecules	10663308	https://www.emolecules.com/cgi-bin/more?vid=10663308

PubMed

Title	Date	PubMed
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.	2012 Dec 13	23137340
Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication.	2013 May	23157601
In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.	2013 Nov	23959304

Patents

Sample Use Guides

In Vivo Use Guide

25 mg (one 25 mg tablet) taken once daily with a meal, is not recommended for patients less than 12 years of age. With rifabutin co-administration, the Edurant dose should be increased to 50 mg (two tablets of 25 mg each) taken once daily with a meal.

Route of Administration: Oral

In Vitro Use Guide

TMC278 (rilpivirine) showed subnanomolar 50% effective concentrations (EC50 values) against wild-type HIV-1 group M isolates (0.07 to 1.01 nM) and nanomolar EC50 values against group O isolates (2.88 to 8.45 nM).

Name

Type

Language

RILPIVIRINE HYDROCHLORIDE

Official Name

English

RILPIVIRINE HCL

Common Name

English

BENZONITRILE, 4-((4-((4-((1E)-2-CYANOETHENYL)-2,6-DIMETHYLPHENYL)AMINO)-2-PYRIMIDINYL)AMINO)-, HYDROCHLORIDE (1:1)

Systematic Name

English

JULUCA COMPONENT RILPIVIRINE HYDROCHLORIDE

Brand Name

English

EVIPLERA COMPONENT RILPIVIRINE HYDROCHLORIDE

Brand Name

English

RILPIVIRINE HYDROCHLORIDE COMPONENT OF ODEFSEY

Common Name

English

RILPIVIRINE HYDROCHLORIDE [USAN]

Common Name

English

RILPIVIRINE HYDROCHLORIDE [VANDF]

Common Name

English

RILPIVIRINE HYDROCHLORIDE COMPONENT OF JULUCA

Brand Name

English

RILPIVIRINE (AS HYDROCHLORIDE)

Common Name

English

TMC-278 HYDROCHLORIDE

Code

English

TMC278 HYDROCHLORIDE

Code

English

RILPIVIRINE HYDROCHLORIDE [JAN]

Common Name

English

ODEFSEY COMPONENT RILPIVIRINE HYDROCHLORIDE

Common Name

English

RILPIVIRINE HYDROCHLORIDE COMPONENT OF EVIPLERA

Brand Name

English

Rilpivirine hydrochloride [WHO-DD]

Common Name

English

RILPIVIRINE HYDROCHLORIDE [MI]

Common Name

English

RILPIVIRINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

EVIPLERA (AUTHORIZED: HIV INFECTIONS)